BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38348678)

  • 1. Sex and Age Differences in the Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Heart Failure: A Prospective Cohort Study.
    Wu S; Li Y; Zhang Y; Su X; Zuo Y; Chen G; Xu G; Chen S; He Y; Wang A
    Circ Heart Fail; 2024 Feb; 17(2):e010841. PubMed ID: 38348678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study.
    Wei Z; Huang Z; Song Z; Zhao W; Zhao D; Tan Y; Chen S; Yang P; Li Y; Wu S
    Diabetol Metab Syndr; 2023 Jun; 15(1):137. PubMed ID: 37355613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
    Wei S; Song J; Xie Y; Huang J; Yang J
    JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
    Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
    Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
    Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
    Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
    Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
    Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Risk of HF and AF.
    Ohno R; Kaneko H; Suzuki Y; Okada A; Matsuoka S; Ueno K; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Node K; Yasunaga H; Komuro I
    JACC Asia; 2023 Dec; 3(6):908-921. PubMed ID: 38155795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults.
    Liu J; Wang G; Wu Y; Guan Y; Luo Z; Zhao G; Jiang Y
    Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of sex-related and thyroid-related hormones with risk of metabolic dysfunction-associated fatty liver disease in T2DM patients.
    Lu W; Li S; Li Y; Zhou J; Wang K; Chen N; Li Z
    BMC Endocr Disord; 2024 Jun; 24(1):84. PubMed ID: 38849804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
    Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
    J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of hepatic steatosis and fibrosis with heart failure and mortality.
    Park J; Kim G; Kim H; Lee J; Lee YB; Jin SM; Hur KY; Kim JH
    Cardiovasc Diabetol; 2021 Sep; 20(1):197. PubMed ID: 34583706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study.
    Kim KS; Hong S; Ahn HY; Park CY
    Diabetes Metab J; 2023 Mar; 47(2):220-231. PubMed ID: 36631994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
    Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
    Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
    Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
    Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers.
    Liu Z; Lin C; Suo C; Zhao R; Jin L; Zhang T; Chen X
    Metabolism; 2022 Feb; 127():154955. PubMed ID: 34915036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
    Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
    Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.